Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Impact · against what's priced in

Eton and Aquestive have established a strategic partnership to commercialize LIBERVANT in the US, providing a new growth vector for Eton and a supply stream for Aquestive. While the deal is positive, the financial impact is deferred until the anticipated commercial availability in April 2027.

ETON+0.60: No priced-in read yet

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

What matters in this story

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

What matters in this story

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

How each ticker is affected

Connected tickers

Track these names every morning.

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

What matters in this story

Next reads from the same story arc

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

What matters in this story

Next reads from the same story arc

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

How each ticker is affected

Connected tickers

Track these names every morning.

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript